Atezolizumab (Tecentriq) Tops Chemo for Platinum-ineligible NSCLC
The checkpoint inhibitor was associated with better survival and adverse events vs single-agent chemo for advanced NSCLC. The study was published as a preprint and has not yet been peer reviewed.
First Look
source https://www.medscape.com/viewarticle/986602?src=rss
First Look
source https://www.medscape.com/viewarticle/986602?src=rss
Comments
Post a Comment